Article

Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA

2024-07-26

Abstract excerpt

Although the first generation of immunotherapies for Alzheimer’s disease (AD) are now clinically approved, amyloid-related imaging abnormalities (ARIA) remain a major safety problem for this class of drugs. Here, we report an antibody transport vehicle (ATV) targeting the transferrin receptor (TfR) for brain delivery of amyloid beta (Aý) antibodies that significantly reduced ARIA-like lesions and improved plaque t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 641da373-daf2-5d62-8d7a-82e13b4610fb
DOI: 10.1101/2024.07.26.604664

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIADOI 10.1101/2024.07.26.604664Read

Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.Semantic proximity Read

Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeysSemantic proximity Read

Expression of amyloid-β antibody via AAV of CNS tropism alleviates Alzheimer’s disease in miceSemantic proximity Read

Brain-Penetrating Peptide and Antibody Radioligands for Proof-of-Concept PET Imaging of Fibrin in Alzheimer’s DiseaseSemantic proximity Read

The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivoSemantic proximity Read

Chimeric Antigen Receptor Macrophages Target and Resorb Amyloid Plaques in a Mouse Model of Alzheimer’s DiseaseSemantic proximity Read

Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like eventsSemantic proximity Read

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read

Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s diseaseSemantic proximity Read

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.Semantic proximity Read

Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody.Semantic proximity Read

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemSemantic proximity Read